Mirabegron 50 mg is a dosage form of mirabegron, a medication used to treat overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency [1]. It functions as a beta-3 adrenergic agonist [2].
How does mirabegron work?
Mirabegron relaxes the detrusor smooth muscle in the bladder during the storage phase, increasing bladder capacity [2]. This action helps to reduce the sudden, urgent need to urinate [3].
What is the difference between mirabegron 25 mg and 50 mg?
Dosage strengths of 25 mg and 50 mg are available for mirabegron. The specific dosage prescribed depends on individual patient needs and tolerance, as determined by a healthcare professional [1].
When might a doctor prescribe 50 mg of mirabegron?
A 50 mg dose of mirabegron is typically prescribed when the 25 mg dose has been used and additional symptom control is needed, or if the patient tolerates it well and requires a higher strength from the outset [1].
What is the patent status for mirabegron?
The U.S. patent for mirabegron, specifically related to its use in treating OAB, has been challenged. Multiple companies have sought to invalidate these patents, aiming to introduce generic versions of the drug [4]. Information on specific patent expiry dates and ongoing litigation can be found on DrugPatentWatch.com [4].
Who makes mirabegron?
Mirabegron was originally developed by Astellas Pharma [5]. Generic versions may be manufactured by various pharmaceutical companies following patent expirations or successful patent challenges [4].
What are the potential side effects of mirabegron?
Common side effects of mirabegron include increased blood pressure, urinary tract infection, headache, and nasopharyngitis (cold-like symptoms) [3].
Can other medications be used for overactive bladder?
Other treatments for overactive bladder include behavioral therapies, pelvic floor muscle exercises, and other medications such as anticholinergics [6].
Sources:
[1] https://www.drugpatentwatch.com/drugs/mirabegron
[2] https://www.drugpatentwatch.com/drug/mirabegron
[3] https://www.nhs.uk/medicines/mirabegron/
[4] https://www.drugpatentwatch.com/drug/mirabegron/patent
[5] https://www.drugpatentwatch.com/company/astellas-pharma
[6] https://www.nhs.uk/conditions/overactive-bladder-oab/treatment/